METTL1 and WRD4 are upregulated in diverse kinds of cancer, including esophageal, liver, colorectal, lung, and nasopharyngeal carcinomas.309–311 In bladder cancer cells and lung cancer cells, METTL1 notably enhances cellular proliferation, migration, and invasion.299 Besides, the expression of WDR4 is significantly correlated with advanced-stage prostate cancer.312 And elevated expression of METTL1 or WDR4 indicates a less favorable prognosis in patients with osteosarcoma.313 The above results highlight their potential as prognostic biomarkers and therapeutic targets in cancer. The gene discussed is METTL1; the disease is prostate cancer.